Data completeness
1/8 — Limited
TURGEX (hexachlorophene) by R-Pharm US. Approved for staphylococcal infections, hiv infections.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TURGEX is a topical aerosol formulation of hexachlorophene, an antimicrobial agent indicated for staphylococcal and HIV infections. The mechanism of action is not fully characterized in available data, but hexachlorophene is a broad-spectrum antimicrobial used primarily for skin antisepsis and infection prevention. This pre-launch product represents R-Pharm US's entry into the topical antimicrobial space.
Growth
As a pre-launch product with no current market data, TURGEX offers significant growth opportunity but carries execution risk; successful launch will require building a lean, agile commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on TURGEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.